EDITORIAL SECTION

Eli Lilly and Company is launching today the Lilly Change the Course Commitment a new global health initiative that aims to achieve parity in patients treated with Lillys innovative diabetes and obesity medicines This means treating as many people with diabetes and obesity in resourcelimited

Eton Pharmaceuticals Inc an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases today announced that the Company has launched IMPAVIDO miltefosine capsules We are excited to be relaunching IMPAVIDO and making Eton Cares available to all patients B...

Multifors is what benchscale parallel bioprocessing should look like in Its built around a simple idea the bioreactor should capture and retain the information that matters so scientists can focus

AVS Bio the Company a leading global provider of critical inputs and services for the bioprocessing and biologics industries today announced it has acquired Biorbyt Ltd Biorbyt a global supplier

Merck known as MSD outside of the United States and Canada and SciBrunch Therapeutics Co Ltd SciBrunch today announced that they have entered into an exclusive global license agreement for SPR an investigational preclinical oral KRAS GD ON inhibitor

The US Food and Drug Administration FDA has granted Breakthrough Therapy designation to Glycomines investigational GLM for the treatment of phosphomannomutase congenital disorder of glycosylation PMMCDG

Elevar Therapeutics has announced that the US Food and Drug Administration FDA has approved LYRFIGTU lirafugratinib as a treatment option for patients with cholangiocarcinoma CCA with an FGFR fusion or other rearrangement

The US Food and Drug Administration FDA has granted Orphan Drug Designation to Kedrion Biopharmas QIVIGY immune globulin intravenous human solution for the potential treatment of Stiff Person Syndrome SPS

Pretzel Therapeutics has received Fast Track Designation from the US Food and Drug Administration FDA for PX an investigational treatment for POLGmediated primary mitochondrial disorders also known as POLG disease

BoomRay Pharmaceuticals has entered into an exclusive global licensing agreement with Novartis Pharma for an undisclosed preclinical radioligand therapy RLT asset